1. WHO. Cardiovascular diseases (CVDs). Available at:
http://www.who.int/mediacentre/factsheets/fs317/en/
(Accessed 3 Jan 2018).
2. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Executive summary: heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation. 133(4):447–54.
3. Gutman D, Golomb G. Liposomal alendronate for the treatment of restenosis. J Control Release. 2012;161(2):619–27.
https://doi.org/10.1016/j.jconrel.2011.11.037
.
4. Aizik G, Grad E, Golomb G. Monocyte-mediated drug delivery systems for the treatment of cardiovascular diseases. Drug Deliv Transl Res. 2018.
https://link.springer.com/article/10.1007%2Fs13346-017-0431-2
.
5. Piraino D, Cimino G, Buccheri D, Dendramis G, Andolina G, Cortese B. Recurrent in-stent restenosis, certainty of its origin, uncertainty about treatment. Int J Cardiol. 2017;230:91–6.
https://doi.org/10.1016/j.ijcard.2016.12.073
.